Do analysts recommend SILO or PHXM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, SILO or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Silo Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silo Pharma $70K 39.75 -$4.23M -$4.36 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Do analysts recommend SILO or MDCX?

Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 5,805.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is SILO or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Silo Pharma -6,726.39% -81.75% -66.35% Medicus Pharma N/A -3,137.84% -263.24%

Do analysts prefer ENSC or SILO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TRAW or SILO?

Traws Pharma presently has a consensus price target of $1.00, suggesting a potential upside of 77.56%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TRAW or SILO more profitable?

Traws Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -23,868.92% -165.52% Silo Pharma -6,726.39% -81.75% -66.35%

Do analysts prefer SILO or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Silo Pharma (SILO) Competitors

$1.75 0.00 (0.00%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$1.75 0.00 (-0.17%)

As of 09/25/2026 07:50 PM Eastern

Compare

SILO vs. PHXM, MDCX, ENSC, TRAW, and CNSP

Should you buy Silo Pharma stock or one of its competitors? Silo Pharma's main competitors and comparable companies include PHAXIAM Therapeutics (PHXM), Medicus Pharma (MDCX), Ensysce Biosciences (ENSC), Traws Pharma (TRAW), and CNS Pharmaceuticals (CNSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silo Pharma compare to PHAXIAM Therapeutics?

Silo Pharma (NASDAQ:SILO) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Silo Pharma had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Silo Pharma and 0 mentions for PHAXIAM Therapeutics. Silo Pharma's average media sentiment score of 0.76 beat PHAXIAM Therapeutics' score of 0.00 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Silo Pharma	Positive
PHAXIAM Therapeutics	Neutral

PHAXIAM Therapeutics has lower revenue, but higher earnings than Silo Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Silo Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. PHAXIAM Therapeutics' return on equity of 0.00% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Silo Pharma beats PHAXIAM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silo Pharma compare to Medicus Pharma?

Silo Pharma (NASDAQ:SILO) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Medicus Pharma had 6 more articles in the media than Silo Pharma. MarketBeat recorded 7 mentions for Medicus Pharma and 1 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.76 beat Medicus Pharma's score of 0.04 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Silo Pharma	Positive
Medicus Pharma	Neutral

Silo Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 5,805.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Silo Pharma has higher revenue and earnings than Medicus Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Medicus Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Medicus Pharma	N/A	-3,137.84%	-263.24%

Summary

Medicus Pharma beats Silo Pharma on 8 of the 15 factors compared between the two stocks.

How does Silo Pharma compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Ensysce Biosciences has a net margin of -280.53% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Ensysce Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Silo Pharma has lower revenue, but higher earnings than Ensysce Biosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.58	-$10.18M	-$2.76	N/A
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A

In the previous week, Ensysce Biosciences had 1 more articles in the media than Silo Pharma. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.76 beat Ensysce Biosciences' score of 0.60 indicating that Silo Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Positive
Silo Pharma	Positive

Summary

Ensysce Biosciences beats Silo Pharma on 7 of the 13 factors compared between the two stocks.

How does Silo Pharma compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Traws Pharma has higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.10	$9.17M	-$1.74	N/A
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A

In the previous week, Traws Pharma had 2 more articles in the media than Silo Pharma. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.76 beat Traws Pharma's score of 0.60 indicating that Silo Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Traws Pharma	Positive
Silo Pharma	Positive

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Traws Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Traws Pharma presently has a consensus price target of $1.00, suggesting a potential upside of 77.56%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Traws Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-23,868.92%	-165.52%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Summary

Traws Pharma beats Silo Pharma on 11 of the 15 factors compared between the two stocks.

How does Silo Pharma compare to CNS Pharmaceuticals?

Silo Pharma (NASDAQ:SILO) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

CNS Pharmaceuticals has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 3.6% of Silo Pharma shares are held by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Silo Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market.

In the previous week, Silo Pharma and Silo Pharma both had 1 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.79 beat Silo Pharma's score of 0.76 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Silo Pharma	Positive
CNS Pharmaceuticals	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Silo Pharma has higher revenue and earnings than CNS Pharmaceuticals. Silo Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

Summary

Silo Pharma beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Silo Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SILO vs. The Competition

Export

Metric	Silo Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.78M	$12.53B	$7.27B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	13.51%
P/E Ratio	-0.40	789.85	274.41	25.75
Price / Sales	39.75	748.37	618.37	86.14
Price / Cash	N/A	91.64	79.23	52.93
Price / Book	0.25	10.51	10.43	6.30
Net Income	-$4.23M	$2.81B	$3.49B	$359.77M
7 Day Performance	-4.89%	-0.96%	-1.25%	-0.23%
1 Month Performance	-30.00%	-3.00%	-4.67%	-3.88%
1 Year Performance	-84.86%	1.06%	15.06%	5.35%

Silo Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SILO Silo Pharma	0.8843 of 5 stars	$1.75 flat	N/A	-84.3%	$2.78M	$70K	N/A	3	Positive News
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MDCX Medicus Pharma	2.4726 of 5 stars	$0.16 -2.8%	$9.00 +5,546.2%	-93.9%	$10.36M	N/A	N/A	16	Short Interest Increase
ENSC Ensysce Biosciences	1.3979 of 5 stars	$0.41 -3.4%	N/A	-81.8%	$8.35M	$5.07M	N/A	10	News Coverage
TRAW Traws Pharma	2.024 of 5 stars	$0.50 +0.7%	$1.00 +98.6%	-70.0%	$7.68M	$2.79M	N/A	7	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SILO) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silo Pharma (SILO) Competitors

SILO vs. PHXM, MDCX, ENSC, TRAW, and CNSP

How does Silo Pharma compare to PHAXIAM Therapeutics?

Summary

How does Silo Pharma compare to Medicus Pharma?

Summary

How does Silo Pharma compare to Ensysce Biosciences?

Summary

How does Silo Pharma compare to Traws Pharma?

Summary

How does Silo Pharma compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silo Pharma (SILO) Competitors

SILO vs. PHXM, MDCX, ENSC, TRAW, and CNSP

How does Silo Pharma compare to PHAXIAM Therapeutics?

Does the media refer more to SILO or PHXM?

Which has stronger earnings and valuation, SILO or PHXM?

Which has more risk & volatility, SILO or PHXM?

Do institutionals & insiders have more ownership in SILO or PHXM?

Is SILO or PHXM more profitable?

Do analysts recommend SILO or PHXM?

Summary

How does Silo Pharma compare to Medicus Pharma?

Does the media prefer SILO or MDCX?

Which has more risk and volatility, SILO or MDCX?

Do institutionals and insiders have more ownership in SILO or MDCX?

Do analysts recommend SILO or MDCX?

Which has better valuation and earnings, SILO or MDCX?

Is SILO or MDCX more profitable?

Summary

How does Silo Pharma compare to Ensysce Biosciences?

Is ENSC or SILO more profitable?

Which has more volatility and risk, ENSC or SILO?

Do analysts prefer ENSC or SILO?

Do insiders and institutionals hold more shares of ENSC or SILO?

Which has stronger valuation & earnings, ENSC or SILO?

Does the media favor ENSC or SILO?

Summary

How does Silo Pharma compare to Traws Pharma?

Which has better earnings and valuation, TRAW or SILO?

Does the media refer more to TRAW or SILO?

Do insiders & institutionals hold more shares of TRAW or SILO?

Which has more risk & volatility, TRAW or SILO?

Do analysts prefer TRAW or SILO?

Is TRAW or SILO more profitable?

Summary

How does Silo Pharma compare to CNS Pharmaceuticals?

Is SILO or CNSP more profitable?

Do insiders and institutionals hold more shares of SILO or CNSP?

Which has more risk and volatility, SILO or CNSP?

Does the media prefer SILO or CNSP?

Do analysts prefer SILO or CNSP?

Which has better earnings and valuation, SILO or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools